Founded by a team of cardiologists and chemical engineers, Sonnest is a healthcare company focused on transforming cardiac ultrasound imaging. Their core mission is to enhance the assessment and monitoring of the heart's perfusion, structure, and function through innovative technology. The company's flagship product, Electrast™, is an electrically sensitive imaging agent that activates with ultrasound and the heart’s local electric field, providing detailed insights into heart tissue viability. Sonnest primarily serves the medical community, including cardiologists and healthcare institutions, through digital platforms.
Notable figures affiliated with Sonnest include leading cardiologists and chemical engineers who drive the company's innovation. The company has garnered attention from investors interested in cutting-edge medical technologies. Key achievements include the development and deployment of Electrast™, which represents a significant advancement in cardiac imaging. Sonnest's impact lies in its potential to improve diagnostic accuracy and patient outcomes in cardiology, positioning it as a pioneering force in the healthcare industry.
